Asciminib, an allosteric inhibitor used to treat BCR::ABL1+ leukemias [44], has demonstrated in vitro [45] and in vivo [46] efficacy for NUP214::ABL1 ALL as long as the ABL1 SH3 domain is present, supporting use of asciminib in NUP214::ABL1 ALL [45, 46]. Here, BCR is linked to acute lymphoblastic leukemia.